Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells
Authors
Keywords
-
Journal
GROWTH FACTORS
Volume 41, Issue 3, Pages 140-151
Publisher
Informa UK Limited
Online
2023-06-28
DOI
10.1080/08977194.2023.2227271
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
- (2022) Na Ryung Choi et al. BMC GASTROENTEROLOGY
- Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
- (2022) Matthew H Kulke et al. ENDOCRINE-RELATED CANCER
- Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
- (2022) Robert J. Motzer et al. Expert Review of Anticancer Therapy
- Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer
- (2021) Stefano Fogli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
- (2020) Soojin Kim et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
- (2019) Nigel Fleeman et al. BMC CANCER
- Improving Pertuzumab production by gene optimization and proper signal peptide selection
- (2017) Amin Ramezani et al. PROTEIN EXPRESSION AND PURIFICATION
- Recent advances of cocktail chemotherapy by combination drug delivery systems
- (2016) Quanyin Hu et al. ADVANCED DRUG DELIVERY REVIEWS
- An overview of the effective combination therapies for the treatment of breast cancer
- (2016) Cristina Núñez et al. BIOMATERIALS
- Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
- (2016) Joleen M. Hubbard et al. Targeted Oncology
- Aflibercept: A Review in Metastatic Colorectal Cancer
- (2015) Yahiya Y. Syed et al. DRUGS
- Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies
- (2015) Rastislav Bahleda et al. ONCOLOGY
- Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
- (2015) Masahito Nakano et al. Cancer Medicine
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
- (2012) P. A. Tang et al. CLINICAL CANCER RESEARCH
- Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
- (2012) Eric Van Cutsem et al. EUROPEAN JOURNAL OF CANCER
- Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion
- (2012) David Boyer et al. OPHTHALMOLOGY
- A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
- (2011) Nicoletta Colombo et al. GYNECOLOGIC ONCOLOGY
- Proteinuria and hypertension with tyrosine kinase inhibitors
- (2011) Praveen Kandula et al. KIDNEY INTERNATIONAL
- Molecular control of endothelial cell behaviour during blood vessel morphogenesis
- (2011) Shane P. Herbert et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
- (2011) Michael Tolentino SURVEY OF OPHTHALMOLOGY
- Bevacizumab and everolimus in the treatment of patients with metastatic melanoma
- (2010) John D. Hainsworth et al. CANCER
- Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2010) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung
- (2010) Natasha B. Leighl et al. Journal of Thoracic Oncology
- Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?
- (2010) C. Vaklavas et al. ONCOLOGIST
- Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
- (2010) Przemyslaw Twardowski et al. UROLOGY
- Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
- (2009) Axel Grothey et al. Nature Reviews Clinical Oncology
- Sorafenib in the treatment of advanced hepatocellular carcinoma
- (2009) AliBen Mousa Saudi Journal of Gastroenterology
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation